Valvanera Laso-Fernandez
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease.
Journal: Atherosclerosis
Published: January 17, 2017
TWEAK blockade decreases atherosclerotic lesion size and progression through suppression of STAT1 signaling in diabetic mice.
Journal: Scientific reports
Published: September 23, 2016
Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: July 23, 2015
Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.
Journal: Atherosclerosis
Published: November 20, 2014
TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages.
Journal: Cardiovascular research
Published: November 11, 2014
Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice.
Journal: Journal of the American Heart Association
Published: August 06, 2014
Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice
Journal: Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
Published: March 27, 2014
Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice.
Journal: Journal of cellular and molecular medicine
Published: July 04, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026